Lenalidomide Grindeks

Lenalidomide, the active ingredient in Lenalidomide Grindeks, is an immunomodulatory imide drug presented as an oral tablet for oral use. It treats multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in combination therapy.

GNH USA supplies Lenalidomide Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related disorders. - Multiple Myeloma: improves progression‑free survival and overall response when used in approved regimens. - Myelodysplastic Syndromes with del(5q): induces transfusion independence and cytogenetic remission. - Mantle Cell Lymphoma (in combination therapy): enhances response rates when combined with other antineoplastic agents.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels causing bleeding tendency. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may lead to dehydration. - Rash: skin eruptions that are usually mild.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: significant liver enzyme elevations or failure.

When prescribing Lenalidomide, clinicians should observe several safety precautions. - Pregnancy: contraindicated; classified as Category X due to teratogenic risk. - Thrombosis risk: assess for clotting disorders and consider prophylactic anticoagulation. - Renal impairment: adjust monitoring in patients with reduced kidney function. - Hematologic monitoring: perform regular blood counts to detect neutropenia or thrombocytopenia. - Drug interactions: avoid concomitant use with strong CYP inducers without supervision. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lenalidomide can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin) combined with high‑dose lenalidomide: increased bleeding risk.

Moderate Interactions (Monitor Closely): - P-glycoprotein inhibitors (e.g., verapamil): may raise plasma levels. - Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity. - Live vaccines: reduced efficacy due to immunomodulation. - NSAIDs: may increase risk of renal dysfunction when combined with lenalidomide.